84359-16-0

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Aminoethylpyridine HCL is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, leveraging its unique structure to facilitate the creation of new medications.
Used in Organic Materials and Coatings Development:
In the development of organic materials and coatings, 3-Aminoethylpyridine HCL is utilized for its specific properties, enhancing the performance and characteristics of these materials for specialized applications.
Used in Neurodegenerative Disease Research:
3-Aminoethylpyridine HCL is used as a potential neuroprotective and anti-inflammatory agent in the research and treatment of neurodegenerative diseases, due to its capacity to potentially mitigate disease progression and symptoms.
Used in Chemical and Pharmaceutical Industries:
3-Aminoethylpyridine HCL is employed across chemical and pharmaceutical industries for its diverse applications, including but not limited to, the synthesis of new compounds, material development, and therapeutic research.

InChI:InChI=1/C7H10N2.ClH/c8-4-3-7-2-1-5-9-6-7;/h1-2,5-6H,3-4,8H2;1H

Upstream product

• 20173-24-4 2-pyridin-3-ylethylamine 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 1401618-70-9 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-3-yl)ethyl)piperidine-4-carboxamide 
• 1379589-66-8 C₂₁H₂₄N₂O₂ 

Relevant academic research and scientific papers

Synthesis of cobalt nanoparticles by pyrolysis of Vitamin B12: A non-noble-metal catalyst for efficient hydrogenation of nitriles

A facile preparation of vitamin B12-derived carbonaceous cobalt particles supported on ceria is reported. The resulting composite material is obtained upon wet impregnation of ceria with natural cyanocobalamin and consecutive pyrolysis under inert conditions. The novel catalyst shows good to excellent performance in the industrially relevant heterogeneous hydrogenation of nitriles to the corresponding primary amines.

Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (le hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands

The soluble acetylcholine binding protein (AChBP) is a homologue of the ligand-binding domain of the nicotinic acetylcholine receptors (nAChR). To guide future fragment-screening using surface plasmon resonance (SPR) biosensor technology as a label-free, direct binding, biophysical screening assay, a focused fragment library was generated based on deconstruction of a set of α7 nAChR selective quinuclidine containing ligands with nanomolar affinities. The interaction characteristics of the fragments and the parent compounds with AChBP were evaluated using an SPR biosensor assay. The data obtained from this direct binding assay correlated well with data from the reference radioligand displacement assay. Ligand efficiencies for different (structural) groups of fragments in the library were correlated to binding with distinct regions of the binding pocket, thereby identifying ligand efficiency hot spots (LE hot spots). These hot spots can be used to identity the most promising hit fragments in a large scale fragment library screen.

Factor Xa inhibitors

The invention provides compounds which specifically inhibit factor Xa activity having the structure A1—A2—(A3)m—B, where m is 0 or 1. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a Ki≦100 μM, preferably ≦2 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of factor Xa and of inhibiting blood clotting in vitro and in an individual and methods of detecting factor Xa levels or activity.